New Frontiers in Biosafety and Biosecurity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. A sustainable balance between innovation and risk: How the "right to science" affects China's medical biotechnology regulatory policy.Computational and structural biotechnology journal · 2024
   Review
2. Towards Better Governance on Biosafety and Biosecurity: China's Advances and Perspectives in Medical Biotechnology Legislation.Frontiers in bioengineering and biotechnology · 2022
   Article
3. Regulatory frameworks can facilitate or hinder the potential for genome editing to contribute to sustainable agricultural development.Frontiers in bioengineering and biotechnology · 2022
   Article
4. Strengthening Biorisk Management Capacities in Burkina Faso: Contribution of the Global Health Security Agenda.Health security
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as